📰 Eric Van Cutsem News
Page 2 - Eric Van Cutsem News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Eric Van Cutsem. Real-time updates on events, politics, business and more.
June 9, 2022
/PRNewswire/ -- Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&D Day on Thursday, June 16, 2022 at 09:00 AM EDT (3:00 PM...
May 26, 2022
STOCKHOLM, May 26, 2022 /PRNewswire/ -- Cantargia (Cantargia AB) (NASDAQ Stockholm: CANTA) today reported extended interim results in first-line pancreatic cancer (PDAC) patients treated with
May 26, 2022
(NASDAQ Stockholm: CANTA) today reported extended interim results in first-line pancreatic cancer (PDAC)...
April 27, 2022
Plenary presentation of Phase 3 tislelizumab trial in first-line RM-NPC Primary analysis of zanubrutinib Phase 2 ROSEWOOD trial in follicular lymphoma Long-term data from zanubrutinib Phase 3
January 16, 2021
(2) Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF (trifluridine/tipiracil) bevacizumab and capecitabine bevacizumab (C-B) in a first-line setting for patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy. 1 The data were announced today during an oral presentation at the 2021 ASCO Gastrointestinal Cancers Symposium (ASCO-GI). Patients with mCRC who are not eligible for chemotherapy face ...
December 16, 2020
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 ... Celyad SADecember 15, 2020 GMT Preliminary data from the expansion cohort are expected during first half 2021 MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chime...
December 15, 2020
Share: Preliminary data from the expansion cohort are expected during first half 2021 MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced the successful dosing of the first patient in the expansion cohort of the Phase 1 alloSHRINK trial for CYAD-101, the Companys allogeneic...
December 15, 2020
Celyad Oncology SA: Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC Regulatory News: Celyad Oncology SA (Euronext Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced the successful dosing of the first patient in the expansion cohort of the Phase 1 alloSHRINK t...